Drug intelligence / Profile preview

Rui Neng

Development stage: Preclinical
Lead developer: Fresenius Kabi
Administration: Oral, Tube Feeding

Overview

Rui Neng is an immune-enhanced enteral nutritional emulsion (TPF-T) manufactured by Fresenius Kabi Huirui Pharmaceutical Co., Ltd. It is a compound preparation designed to provide comprehensive nutritional support or supplementation. The formulation includes protein, fat, carbohydrates, and various micronutrients, and is notably enriched with omega-3 fatty acids and ribonucleotides. It is indicated for patients suffering from malnutrition, particularly oncology patients experiencing cachexia, anorexia, or difficulties with chewing and swallowing, as well as other conditions requiring increased intake of fat or omega-3 fatty acids. Rui Neng can be administered orally or via tube feeding.

Brand names: Rui Neng瑞能
Other names: Enteral Nutritional Emulsion (TPF-T)肠内营养乳剂(TPF-T)

Beyond the preview

Go deeper on Rui Neng.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rui Neng.

Explore the full profile